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The antineoplastic paclitaxel is associated with negative affective outcomes, such as depression, anxiety,
and decreased quality of life during treatment and convalescence. With the Baby Boomer population
approaching peak cancer age, it is dire that the mechanisms behind paclitaxel-induced changes in mood
are uncovered. Cancer-free male and female C57BL/6J mice were treated with one set of four injections
of vehicle or paclitaxel (32mg/kg cumulative), or two sets of four injections of vehicle or paclitaxel
(64mg/kg cumulative), and periodically assessed for depression-like behaviors. Paclitaxel caused
significant, time-dependent deficits in sucrose preference and operant responding for palatable food.
Because there is growing evidence to support the role of kappa opioid receptors (KORs) in stress-
mediated depression and reward dysfunction, we investigated KOR signaling as a putative mechanism of
paclitaxel-induced depression-like behaviors. The selective KOR antagonist norbinaltorphimine (norBNI)
reversed paclitaxel-induced attenuation of sucrose preference. At the molecular level, paclitaxel time-
dependently induced an increase in the expression of Prodynorphin mRNA, the precursor for endogenous
KOR agonists, in the nucleus accumbens (NAc). Using the [35S]GTPγS assay, we discovered that a
history of paclitaxel time-dependently attenuated activation of dopamine D2 receptors (D2R) and KORs in
the NAc but not caudate putamen. These data suggest that paclitaxel-induced changes in affect-like
behavior may be due to time- and region-dependent dysregulation of KOR and D2R signaling. These
observations help to establish the roles of KOR and D2R systems in paclitaxel-induced disruption of
behavioral reward, thus revealing potential neurochemical targets for therapeutic intervention in cancer
survivors with treatment-resistant depression.
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A) PAC did not displace
[3H]Diprenorphine binding in
mKOR-expressing CHO cells
at concentrations up to 10
µM (data expressed as
Mean±SEM
[3H]Diprenorphine binding,
n=4-5).
B) PAC did not stimulate
guanine nucleotide
exchange in NAc from naïve
mice at similar
concentrations (data
expressed as Mean±SEM %
basal stimulation, n=3-5).
Further, primary binding
assays performed by the
Psychoactive Drug
Screening Program did not
identify likely targets. These
data suggest that PAC is not
a direct KOR or GPCR G(i/o)
agonist.
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Fig. 4: The results of the norBNI experiment suggest that increased endogenous
KOR agonists cause PAC-induced reward deficit. In order to test this hypothesis,
Veh or 32mg/kg PAC mice were sacrificed at Day 7 or Day 70. Total RNA was
extracted with TRIzol®, followed by reverse transcription with iScript™ cDNA
Synthesis Kit (BIO-RAD). Real-time PCR was performed by reacting cDNA with
TaqMan® Universal PCR Master Mix and mouse Prodynorphin or β-Actin FAM-
MGB probes. A) Systemic PAC increased Pdyn mRNA, the precursor for
endogenous KOR agonists, in the NAc at Day 7. B) There was no change in Pdyn
levels in CPu at Day 7. Further, history of PAC had no effect at Day 70 in either
tissue. Data are expressed as relative to Actb mRNA using the 2-ΔΔCt method; t-test,
*p <0.05.
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Fig. 1: 32mg/kg PAC and Veh mice were given a single injection of saline or the selective, long-lasting KOR antagonist norBNI (10 mg/kg, s.c.) on Day 6, and 2% sucrose preference in the 2-
bottle choice test (A) was measured 24 hours later (Day 7). B) PAC induced deficit for sucrose preference (Tukey’s multiple comparisons test, *p <0.0001 PAC/Saline vs. Veh/Saline). norBNI
fully reversed sucrose preference deficit (#p <0.0001 PAC/norBNI vs. PAC/Saline. C) Consistent with our previous reports, 32mg/kg PAC induced mechanical hypersensitivity in the von Frey
test (Two-way ANOVA: F(1,44) = 722.2, *p <0.0001 PAC vs. Veh). norBNI did not reverse PAC-induced mechanical hypersensitivity. Data are expressed as Mean±SEM, n=8/group. These
findings support our hypothesis that altered KOR signaling contributes directly to PAC-induced reward deficit. Importantly, we demonstrate that nociception and anhedonia-like behavior are
separable facets of chemotherapy-induced neuropathic pain states.
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Fig. 5: A) Apparatus: operant chamber outfitted with nose-pokes and a dispenser of Purified Rodent Diet, lightly sweetened 14mg pellets. The inactive nose-poke is plugged. B) Food-regulated
male mice responded on a fixed-ratio 10 schedule of reinforcement. Acute 32mg/kg PAC treatment did not change rate of responding during 15 min sessions. Arrows indicate injections. Data
expressed as Mean±SEM, n=7-9. C) The subjects from B were presented with the Richardson & Roberts4 progressive ratio ( [5e (R*0.2)] - 5, where R is the # of food reinforcers earned + 1)
during 1 hr sessions. A true break point was not reached when food-regulated or on free-feed, tested in sessions up to 4 hrs long. However, PAC-treated mice had a drop in total number of
nose-pokes starting at Week 7, suggesting motivation deficit; two-way ANOVA: F(1,73) = 6.570, *p <0.05, n=7-9. Data expressed as total nose-pokes per session, normalized to Veh.
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Mouse Model of Paclitaxel-Induced Neuropathy
Fig. 2: In order to determine if PAC time-dependently modulates KOR or other opioid receptor activation, Veh and 32mg/kg PAC mice were sacrificed at Day 7 and Day 28 (A). B) Schematic of
the [35S]GTPγS assay. C) 32mg/kg PAC attenuated U50,488H (KOR agonist)-stimulated [35S]GTPγS binding in NAc homogenates at Day 7 (Two-way ANOVA: F(1,181) = 4.180, *p<0.05) and
decreased U50,488H potency in PAC-treated mice (EC50 = 23.3±5.4 nM) as compared to vehicle-treated mice (EC50 = 5.6±1.6 nM); t-test *p<0.01. This shift resolved by Day 28. No shift was
observed in CPu at either Day 7 or Day 28. D) PAC had no effect on DAMGO (MOR agonist)-stimulated [35S]GTPγS binding in NAc or CPu at either time point. PAC had no effect on basal
activity in either tissue at either time point. These results suggest that PAC has time- (Day 7), region- (NAc), and receptor- (KOR) specific effects.
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1: PAC decreases sucrose preference via KOR. 
2: PAC has temporal-, region-, and receptor-selective effects in the brain.
3: PAC induces time- and region-dependent endogenous KOR agonists.
4: PAC is not a KOR agonist. 
5: PAC has work-, time-, and sex-dependent effects on operant responding. 
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[35S]guanosine-5’-O-(γ-thio)-
triphosphate ([35S]GTPγS)
assay. Agonist-stimulated
guanine nucleotide exchange
was measured in NAc and
CPu. Data are expressed as
Mean±SEM % Stimulation (net
stimulated [35S]GTPγS binding
[fmol/mg] / basal [35S]GTPγS
binding [fmol/mg] x 100%).
• No efficacious treatment for paclitaxel-induced depression in 
cancer survivors.1
• PAC-induced depression can last for up to 5 years or longer 
following cessation of treatment.2
• We previously characterized the effects of a clinically relevant 
dosing schedule of PAC on behavior in male C57BL/6J mice over 
the course of 0-4 months.3
• Here, we further characterize PAC-induced changes in affect-like 
behavior over the course of 6 months, and we investigate 
putative molecular mechanisms. 
Hypothesis: Negative affective state produced by PAC is mediated 
by kappa opioid receptor signaling in the nucleus accumbens.
(Toma et. al, 2017)
2% 
Sucrose
To further characterize the model used by Toma
(2017), adult (8-10 wks) C57BL/6J mice
received one set of four injections of Vehicle
(1:1:18 [ethanol:kolliphor:saline]) or PAC
(8mg/kg x 4 = 32mg/kg cumulative). Injections
were every other day.
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(Manuel et al., 2015)
B) C)
B) CPuA) NAc B)
A)
A)
A) B)
Pilot Data: F) 32mg/kg PAC exacerbated
U50,488H-induced depression of operant
responding for sucrose during week 11, Richardson
& Roberts ratio. Two-way ANOVA: F(1,38) = 4.6, p
<0.05, n=7-8. Sidak’s multiple comparisons test
identified 3mg/kg U50,488H to have a greater impact
on PAC mice, *p <0.05. G) 64mg/kg PAC did not
interact with U50,488H-induced depression of
operant responding when tested at week 19, 2x ratio,
n=6-8.
B)A) C)
G) 64mg/kg; 19 wksF) 32mg/kg; 11 wks
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D) E)
D) A new cohort of male mice was challenged with a variety of progressive ratios of increasing steepness in order to determine the true break point. Of note, the ratios of 2x (1, 2, 4, 8, 16, 32...)
and 10x (1, 10, 100, 1000...) produced break points in a quarter of the mice during 1 hr sessions. Data were collected weekly using both steep ratios. The 10x ratio was not sensitive to changes
in motivation, whereas the 2x ratio revealed ~50% decrease in operant responding, which first emerged 4 weeks after completion of 64mg/kg PAC treatment and began to resolve after 12
weeks; two-way ANOVA: F(1,191) = 24.00, #p <0.0001, n=6-8. E) 64mg/kg PAC had no effect on free-feeding females performing 2x progressive ratio, n=10.
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• Mice had temporal-, region-, and receptor-selective changes in their brains.
• PAC is not a direct KOR agonist, but may activate KOR indirectly via 
upregulating prodynorphin mRNA.
• Mice show work-, time-, and sex-dependent effects on operant responding 
for mildly sweetened food pellets.
• Preliminary data suggest that onset, duration, and magnitude of deficit in 
operant responding may be PAC dose-dependent.
• Future studies will further investigate the effects of KOR modulators on 
PAC-induced changes in affect-like behavior.
Fig. 4: Because systemic PAC has well-documented effects on
mood in human patients, we investigated if PAC is a KOR ligand.
For select behavior
experiments, mice
received two sets of four
injections of Veh or PAC
(8mg/kg x 8 = 64mg/kg
cumulative). Sets were
separated by 3 days.
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